E
Enumerix
Innovative digital biology solutions with high-performance, low-cost PCR technology for molecular biology labs
About Enumerix
Enumerix is a pioneering company in the digital biology sector, offering cutting-edge PCR (Polymerase Chain Reaction) technology that simplifies and enhances molecular biology processes. The company serves molecular biology labs, researchers, and biotech firms by providing a unique spin column format that generates 30 million partitions per sample using a standard centrifuge. This technology offers 1500 times more partitions than conventional digital PCR, making it highly efficient for detecting rare molecules in diluted samples such as cell-free DNA (cfDNA).
Enumerix operates in the genomics and biotechnology market, focusing on innovations that unlock simplicity, low cost, and high performance. The business model revolves around selling its proprietary UltraPCR technology and related consumables to labs and research institutions. Revenue is generated through the sale of these products and potentially through licensing agreements for their patented technologies.
The company's multidisciplinary team boasts 60,000 citations and 100 patents, reflecting their proven success in the genomics space. Enumerix's mission is to revolutionize digital biology, making advanced molecular techniques accessible for everyday use.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2019
- Headquarters
- Palo Alto, United States
- Employees
- 34
- Open positions
- None listed
- Dealroom signal
- 55.4/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Biotech and Pharma, DT and LS
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| EARLY VC✓Equity / VC | May 2026 | $26M | $104M | Primer Ventures · F-Prime · ARCH Venture Partners | ↗ |
Growth signals
Latest recorded traffic for Enumerix is 2.9K monthly website visits, down 29.3% over the last three months. Enumerix's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
ARCH Venture Partners
Primer Ventures
F-Prime
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Enumerix on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Enumerix’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.